Patiromer (Veltassa®)
Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.
| NCPE Assessment Process | Complete |
| Rapid review received | 11/10/2017 |
| Rapid review completed | 17/11/2017 |
| Rapid Review outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 20/11/2017 |
| Pre-submission consultation with Applicant | 16/01/2018 |
| Submission received from Applicant | 13/04/2018 |
| Preliminary review sent to Applicant | 15/10/2018 |
| NCPE assessment re-commenced | 13/11/2018 |
| Factual accuracy sent to Applicant | 21/01/2019 |
| NCPE assessment re-commenced | 04/02/2019 |
| NCPE assessment completed | 13/02/2019 |
| NCPE assessment outcome | The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
Re-submission of HTA
| NCPE Assessment Process | Ongoing |
| Re-submission of HTA commissioned by the HSE | 30/06/2020 |
| Pre-submission consultation with Applicant | 23/11/2020 |
| Current status | Awaiting HTA submission from Applicant |